For infectious diseases, assays, neutralization studies and epitope mapping related to antibody function are crucial for the development of vaccines and therapies. In cancer, screening clinical candidates and determining cellular responses is the basis for the development of small molecules and monoclonal antibodies, and elucidating T cells phenotype, effector function, and secretion of cytokine are prerequisites for obtaining advanced cell therapy.
Time is precious. Whether it is identifying candidate vaccines that can induce the production of robust neutralizing antibodies, or developing cancer therapies with life-saving potential, speed is crucial. Sedolis iQue® High-throughput Flow Cytometry platform aims to simplify flow cytometry without decreasing advanced analytical capabilities, thereby expanding its application in more laboratories and users.
Infectious Disease Application
The emergence of new pathogens is constantly driving a significant change in the development speed of new vaccines and new therapies to fight infectious diseases. The time to obtain results in discovery and development is crucial. An increasingly powerful high-throughput analytical technology available to drug and vaccine developers of any professional level can be used to accelerate the workflow of viral biology and host immune response characterization.
Figure 1 Quick quantitative ADCP analysis using iQue® platform Design
Oncology Immunology Application
iQue® flow cytometry system also brings throughput advantages to the development of advanced cancer treatments including multispecific antibodies, antibody-drug conjugates (ADCs) and subsequent cell transfer therapy, as well as small molecule and monoclonal antibodies. The multiplexing function of this platform allows for drug candidate screening, phenotyping, functional studies and cytokine assays, and cell subpopulation characterization of cell therapy. When source materials (such as patient-derived cells) are limited, the analytical miniaturization capabilities of the iQue® platform are particularly important for the application of oncology immunology.
Figure 2 T cell activation
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-